• Tue, August 6, 2024

Jonathan Wolleben Maintained (BCRX) at Buy with Increased Target to $16 on, Aug 6th, 2024

Jonathan Wolleben of JMP Securities, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Buy with Increased Target from $15 to $16 on, Aug 6th, 2024.

Jonathan has made no other calls on BCRX in the last 4 months.



There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, 0 agree with Jonathan's Rating of Hold.



This is the rating of the analyst that currently disagrees with Jonathan


  • Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $12 on, Tuesday, May 7th, 2024

Like: 👍